Loading
A phase 2 trial of Fluoroestradiol F-18 in Breast cancer, run by City of Hope Medical Center, now recruiting.
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer is a phase 2 interventional study registered as NCT06260033 by City of Hope Medical Center, with 18 participants planned, started 2024-07-23 and due to reach its primary completion in 2026-10-29. Interventions recorded: Biospecimen Collection, Bone Scan, Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy. Conditions recorded: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma.
Linked to the drug Fluoroestradiol F-18 because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Fluoroestradiol F-18 (FES PET), FES, Breast cancer (all types) and the tag pipeline.
Shares Fluoroestradiol F-18 (FES PET), FES, Breast cancer (all types) and the tag pipeline.
Shares Fluoroestradiol F-18 (FES PET), FES, Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.